Background-While probabilistic projection methods for projecting life expectancy exist, few account for covariates related to life expectancy. Generalized HIV/AIDS epidemics have a large, immediate negative impact on the life expectancy in a country, but this impact can be mitigated by widespread use of antiretroviral therapy (ART). Thus, projection methods for countries with generalized HIV/AIDS epidemics could be improved by accounting for HIV prevalence, the future course of the epidemic, and ART coverage.
Introduction
Probabilistic projections of mortality measures are important for many applications, including population projection and pension and healthcare planning. Until recently, most projections of mortality measures were deterministic, although the United Nations (UN) has recently started to base its official projections of mortality on probabilistic methods. Most projections, deterministic or probabilistic, do not incorporate cause-of-death information or other covariates. used today. It requires at least three time periods of age-specific death rates, an amount of data that is not available in many countries. The method assumes that the logarithm of the age-specific death rates will increase linearly in the future, which may not be optimal for long-term projections (Lee and Miller 2001) . Alho and Spencer (1985) developed a method for incorporating uncertainty in population forecasting, addressing fertility, mortality and migration separately. However, the authors state this method is designed to be used for shortterm projections. Girosi and King (2008) proposed a Bayesian method for smoothing age-specific death rates over both age and time. Even though this method allows for the incorporation of covariates, it has been shown to perform well only for countries with good vital registration data. Like the Lee-Carter method, the Girosi and King (2008) method assumes a constant rate of increase. Lutz, Sanderson, and Scherbov (1998) developed an expert-based method for probabilistic projections of population that incorporates subjective probabilistic projections for several demographic measures, including life expectancy. Raftery et al. (2013) and Raftery, Lalic, and Gerland (2014) presented a Bayesian hierarchical model (BHM) for projecting male and female life expectancy probabilistically and jointly for all countries of the world to 2100, and the UN now uses this method for its official mortality projections and as an input for its official population projections (United Nations 2015) . We extend the model in Raftery et al. (2013) to include covariate information about generalized HIV epidemic prevalence and coverage of antiretroviral therapy (ART) in each country. A country is said to have a generalized HIV/AIDS epidemic when HIV prevalence is greater than 1% in the general population and is not concentrated in at-risk subgroups. While there are many diseases that have a high impact on mortality in a given country, the generalized HIV epidemic is unusual in that it dramatically increases agespecific mortality rates at prime adult ages. Its demographic impact is therefore different from that of other diseases, which tend primarily to affect mortality rates for very young and/or older ages. Figure 1 shows the rise of the HIV epidemic and the corresponding evolution of life expectancy at birth in Botswana. There was a sharp lowering of life expectancy with the rise of the epidemic and then a rapid recovery to pre-epidemic levels following the widespread introduction of ART.
To incorporate covariate information into a probabilistic projection model, we must also have a method for projecting the covariate of interest into the future. UNAIDS developed the Spectrum/EPP methodology for projecting HIV prevalence and demographic measures, including life expectancy at birth, while accounting for HIV prevalence and ART coverage, among other things (Stover, Brown, and Marston 2012; Stanecki, Garnett, and Ghys 2012; Futures Institute 2014) . The method is quite complicated and requires fine-grained data on a number of demographic and health measures for each country. It is recommended for reconstructing the HIV epidemic, including the time of onset, in a particular country and for projecting the epidemic up to five years into the future. It is not designed for long-term HIV prevalence projections, which in turn are important for long-term population projections (UNAIDS 2014: 9) .
We use a version of the EPP package for projections of HIV prevalence to 2100 written in R (Brown et al. 2010) . We develop a model for projecting life expectancy at birth while accounting for HIV prevalence and ART coverage that is simpler and more practical for long-term projections than Bayesian probabilistic methods.
Methodology

Data
We use estimates of past and present female life expectancy at birth from the United Nations World Population Prospects (WPP) 2015 Revision (United Nations 2015) for 201 countries.
The UN produces estimates of past and present period life expectancy at birth and agespecific mortality rates by five-year periods and five-year age groups; these are updated every two years. There are estimates for each country of the world for each five-year period from 1950 to 2015. We do not use life expectancy inputs for Cambodia and Rwanda from the time periods of the genocides in these countries.
To fit the model, we use UNAIDS estimates of past HIV prevalence and ART coverage for 40 countries with generalized epidemics. We use 1,000 trajectories of HIV prevalence, using the same assumptions as Brown et al. (2010) . Additionally, we use a single deterministic trajectory of ART coverage from UNAIDS in the projection stage. ART is relatively new in many generalized epidemic countries, with the first coverage estimates available for the time period [2000] [2001] [2002] [2003] [2004] [2005] . Data relating to coverage tends to be noisy. We code HIV prevalence as zero for all countries not experiencing a generalized HIV epidemic.
Review of joint probabilistic projections of male and female life expectancy
Our methodology builds on the Bayesian hierarchical model for joint probabilistic projection of female and male life expectancy used by the UN (Raftery et al. 2013; Raftery, Lalic, and Gerland 2014) , which proceeds as follows: First, we estimate the Bayesian hierarchical model for female life expectancy using Markov chain Monte Carlo (MCMC), then we make probabilistic projections of female life expectancy from the present day to 2100. We then make projections of male expectancy based on the projected values of female life expectancy (Raftery, Lalic, and Gerland 2014) . The model provides a way for projection for one country to be improved using information from other countries.
At the lowest observation level, the Bayesian hierarchical model for female life expectancy at birth is
where ℓ c,t is the female life expectancy at birth for country c in time period t, g(·|θ (c) ) is the expected five-year gain in life expectancy, modeled as a double logistic function of current life expectancy and governed by country-specific parameters, θ (c) , ε c,t+1 is a random perturbation around the expected gain, and f(ℓ c,t ) is a smooth function of life expectancy. The double logistic function for country c is
where θ
c ), A 1 , A 2 are constants. The parameter z c is the expected country-specific asymptotic five-year gain in life expectancy. The other parameters govern the maximum value and the pace of rise and fall of expected five-year gains in life expectancy.
At the second level of the model, the country-specific parameters θ (c) are assumed to be drawn from the following truncated normal-world distributions:
The truncation of the normal distribution for z c is informed by observed gains in maximum age at death among countries with the highest life expectancies (Wilmoth et al. 2000) . At the third, top level of the model, hyperprior distributions are specified for the world parameters θ = (Δ 1 , Δ 2 , Δ 3 , Δ 4 , k, z, ω). The hyperpriors are proper and diffuse. See Raftery et al.
(2013) for more details.
The Bayesian hierarchical model is estimated using MCMC via Metropolis-Hastings, Gibbs sampling, and slice sampling steps, yielding a joint posterior distribution of all the model parameters (Raftery et al. 2013 ). The smooth function f(ℓ c,t ), specifying how the variance of the perturbations depends on life expectancy, is estimated separately and is treated as known in the MCMC algorithm. Note that the overall variance parameter ω is not treated as known and is estimated by the MCMC algorithm.
Once the model has been estimated, projections of life expectancy are made based on each posterior sample of θ (c) and a random perturbation, ε c,t+1 , drawn from a N(0, (ωf(ℓ c,t )) 2 ) distribution, where ω is drawn from the posterior distribution. After female projections of life expectancy are made, projections of male life expectancy, ℓ c, t m , are made by modeling the gap between the two (Raftery, Lalic, and Gerland 2014).
Probabilistic projections of life expectancy accounting for HIV prevalence
We expand the BHM to account for generalized HIV/AIDS epidemics by adding a co-variate to the observation level of the model. To define the covariate, let HIV c,t and ART c,t be the HIV prevalence and ART coverage in percent of country c at time period t, respectively. Then the quantity HnA c,t = HIV c,t × (100 -ART c,t ) can be viewed as approximating the percentage of the population who are infected but do not receive ART therapy. The covariate we found to best predict change in life expectancy was the change in this quantity, namely ΔHnA c,t-1 = HnA c,t -HnA c,t-1 . Our expanded observation equation is then
The parameter β HnA is constant across countries and is estimated by MCMC along with the other parameters of the Bayesian hierarchical model. It has a diffuse prior distribution, chosen to be proper (i.e., a valid probability distribution) but spread out enough that reasonable changes in it would have little impact on the final inference. Specifically, the prior distribution of β HnA that we use is N 0,0.25 × After estimation, we project female life expectancy in the same manner as outlined in Section 2.2. However, we make a projection based on each posterior sample of (θ (c) , β Hna ) and a random perturbation. We account for uncertainty in the HIV trajectories by using 1,000 yearly trajectories of HIV projections from EPP (Brown et al. 2010) . For each country c and year t, we find the median, z t,c , of projected adult HIV prevalence output from EPP.
We use a single UNAIDS deterministic projection to 2100 as a baseline reference, and we construct 1,000 trajectories from the single UNAIDS trajectory by using 1,000 multipliers of the form
, at each time point t for k = 1, …, 1000, where z t, c k is prevalence at time t in country c in the k-simulated trajectory. Thus the UNAIDS deterministic trajectory serves as the median trajectory of HIV prevalence to 2100, and the EPP trajectories determine the uncertainty. We construct five-year averages from the yearly trajectories to be used in the projection stage. From these, we use a single deterministic trajectory of ART coverage to compute 1,000 trajectories of ΔHnA c,t for all countries. We sample from the 1,000 trajectories of ΔHnA c,t with equal probability to be used in the projection stage.
For the country of Liberia, the prevalence is projected to be so low in the future (close to 0) that the multipliers are unrealistically large. We therefore treated it slightly differently. For this country we calculated z t, c k − z t, c for each time point t. We then added this distance to the UNAIDS trajectory to yield 1,000 trajectories with the UNAIDS trajectory as the median and borrowed the uncertainty from the EPP trajectories.
The methods of Raftery et al. (2013) and Raftery, Lalic, and Gerland (2014) did not use the generalized HIV epidemic countries in model estimations. By contrast, our estimation of the BHM does include these countries. The covariate values are set to zero for nonepidemic countries. Thus, the estimation of country-specific parameters and the projection of life expectancy for nonepidemic countries change negligibly; we are effectively fitting the model in (1) for these countries. For epidemic countries, the model in (2) allows us to adjust for the effects of HIV on life expectancy in the linear term and to interpret g(·|θ (c) ) as the expected five-year gain in life expectancy in the absence of the epidemic. Even though high HIV prevalence takes a big toll on a country's life expectancy at birth in the absence of ART, ART extends an infected person's life substantially. Several epidemiological case studies show that HIV-positive individuals have nearly normal life expectancy when treated with ART (Mills et al. 2011; Johnson et al. 2013) . In a country where ART coverage is high, a generalized HIV epidemic affects life expectancy like a chronic disease would (Deeks, Lewin, and Havlir 2013) .
Similarly to Raftery et al. (2013) , the distribution of the random perturbations in the projection stage is ε c,t+1 ∼ N(0, (ω × f(ℓ c,t,i ) 2 ), where ω is a model parameter, f(ℓ c,t,i ) is a smooth function, and i is an indicator of generalized HIV epidemic. To estimate f(ℓ c,t,i ), we fit the model in (2) using the same function f(ℓ c,t ) as used by Raftery et al. (2013) . Then, using mean posterior estimates of g(ℓ c,t |θ (c) ), we projected life expectancy forward from 1950-1955 to the 2010-2015 period using only the mean model in (2) with no random perturbations. We then calculated absolute residuals for these projections. We fit LOWESS curves to the absolute residuals for nonepidemic countries and for epidemic countries separately. A LOWESS curve fits a smooth curve to points using weighted least squares in estimation.
These curves can be seen in Figure 2 . The black dots represent the absolute residuals from HIV countries, and the red LOWESS curve is fit to these points. The gray dots represent the absolute residuals from nonepidemic countries, and the blue curve is fit to these points. Here one can see that the countries experiencing a generalized epidemic have more variability than the nonepidemic countries. This variability is propagated into the future for epidemic countries. For nonepidemic countries, f(ℓ c,t,i=nonHIV ) is the blue curve in Figure 2 . For epidemic countries f(ℓ c,t,i=HIV ) is the maximum of the blue and red curves up to the highest observed life expectancy for an HIV country to date, namely 78.1. For projected female life expectancies above 78.1 years, we use the blue curve plus a constant that is equal to the vertical difference between the red and blue curves at 78.1 years.
Model validation
We performed predictive out-of-sample validation to assess our model. First, we fit the model in (2) The last three columns contain our metrics. The mean absolute error (MAE) is calculated as
where ℓĉ ,t is the median projection of female life expectancy for country c in time period t. In (3), is the set of countries involved in calculating the MAE (either the HIV countries or all countries), is the set of five-year time periods involved as shown in the third column, and n is the number of country-time period combinations as shown in the fourth column. The last two columns show the proportion of countries whose 80% and 95% posterior predictive intervals contain the observed life expectancy in the validation period of interest.
In all the out-of-sample scenarios, we saw substantial improvements in coverage for HIV countries after accounting for HIV prevalence and ART coverage. We broke down the twoperiod out-of-sample exercise into the two projection periods to get more detailed information about the HIV countries. In 2005-2010, the model with no covariates missed 15 out of 40 HIV countries at the 95% level. When we accounted for HIV prevalence and ART coverage, the number of HIV countries missed went down by over half, to only 7 at the 95% level. For 2010-2015, the model with no covariates missed 14 out of 29 HIV countries at the 95% level, while accounting for HIV prevalence and ART coverage reduced this to only two HIV countries in the time period 2010-2015. In the leave-two-time-periods-out validation exercise, we saw a decrease in MAE for the HIV countries in every case, while the MAE remained unchanged for the non-HIV countries. For the non-HIV countries, the addition of the covariate in the model in (2) changed coverage negligibly.
When fitting the model using data from 1950-1955 up to 2005-2010 and projecting female life expectancy for 2010-2015, we also saw improvements. Our coverage was much closer to the target nominal proportion for HIV countries after accounting for HIV prevalence and ART coverage. We missed 11 HIV countries out of 29 in the model with no covariates but only one HIV country after accounting for the HIV epidemic. The MAE also decreased when accounting for HIV prevalence and ART coverage.
Predictive validation results for male life expectancy are shown in Table 2 in Appendix B, and the conclusions are broadly similar.
The current method used by the UN to project life expectancy in the presence of the HIV epidemic is the Spectrum/EPP package (Futures Institute 2014; Stanecki, Garnett, and Ghys 2012; Stover, Brown, and Marston 2012). However, Spectrum is a complicated method with heavy data demands and is intended only for short-term projections up to five years into the future. Therefore, an important question is whether our simpler method can produce shortterm projections similar to those of the more complex Spectrum method.
To answer this, we fit our model (2) In summary, our model produces similar projections to the current methodology designed for short-term projections, but using a much simpler model with smaller data requirements.
Case studies
We now give specific results for five countries that illustrate specific aspects of the method. Results for all countries considered here as having generalized epidemics are given for female life expectancy in Appendix A and for male life expectancy in Appendix B.
Medium epidemic: Nigeria
Nigeria, located in West Africa, is the most populous country on the continent. It had an HIV prevalence of 3.6% in 2010-2015. Figure 4 shows a comparison between projections of life expectancy under the model (1) with no covariates in blue and the model (2) with the HIV covariate in red.
The median projections of female life expectancy are higher than those projected when not accounting for the HIV/AIDS epidemic, and accounting for the epidemic leads to more uncertainty about the future trajectory of female life expectancy in Nigeria.
Medium epidemic: Kenya
Kenya in East Africa has a medium-sized epidemic with HIV prevalence at 5.7% in 2010-2015. Figure 5 shows that Kenya has already recovered to pre-epidemic life expectancy levels. After accounting for HIV prevalence and ART coverage, we project a slightly higher median female life expectancy to 2100 with more uncertainty at all time periods.
Widespread epidemic: South Africa
South Africa has the largest HIV/AIDS epidemic in the world in absolute numbers. The estimated average prevalence in the 2010-2015 time period was 17.5% (United Nations 2015). Figure 6 shows a comparison between projections of life expectancy under the model in (1) in blue and the model in (2) in red. Figure 6 reflects the clear impact of ART coverage on recovery in life expectancy under a large epidemic. After accounting for HIV prevalence and ART coverage, we project an initial recovery to pre-epidemic life expectancy levels with a steady rise through the end of the century. When not accounting for the HIV epidemic and, particularly, ART coverage, the model projects median end-of-century life expectancy only slightly higher than South Africa's life expectancy before the HIV/AIDS epidemic. Thus, not accounting for HIV and ART in the model leads to projections that are contrary to the epidemiological literature referenced in Section 2.3, showing that life expectancy recovers quickly after a scale-up of ART coverage. . In both cases, our interval captures the outcome, whether measured by the UN or Statistics South Africa, and in particular the rapid increase in life expectancy due to the widespread rollout of ART.
Widespread epidemic: Botswana
HIV prevalence rose early and quickly in Botswana, and the ART scale-up was also quick. This led to a rapid recovery in life expectancy in the 2005-2010 time period. After accounting for the epidemic and ART, we project a slightly slower rise in median life expectancy with more certainty than the model that does not account for the epidemic. This is in agreement with the epidemiological literature cited in Section 2.3 suggesting that HIV/ AIDS will affect life expectancy as a chronic disease would after ART has become pervasive.
No epidemic: Germany
Germany is an example of a country that does not have a generalized epidemic. As can be seen in Figure 8 , projections of life expectancy under the model in (1) and the model in (2) differ negligibly in both median and uncertainty.
Discussion
We have developed a probabilistic method for projecting life expectancy while accounting for generalized HIV/AIDS prevalence and ART coverage. Our method has relatively modest data requirements. Through predictive validation we have shown that our method improves upon life expectancy projections for countries with generalized HIV/AIDS epidemics using the method in Raftery et al. (2013) , while leaving projections for nonepidemic countries essentially unchanged. Our projections improve in terms of both the mean absolute error of point predictions and the calibration of predictive intervals. Our method produces similar short-term projections to the UNAIDS Spectrum/EPP package, with a simpler model that requires much less data. Moreover, the method can produce long-term projections out to 2100.
Our model reflects the literature consensus mentioned in Section 2.3 that HIV prevalence will have large impacts on life expectancy only in the absence of ART. Once ART covers a large proportion of the infected population, there is a one-time gain in life expectancy towards pre-epidemic levels, and the effects will be modest afterwards.
Our method can be combined with population projection methods to make probabilistic population projections which account for the HIV/AIDS epidemic. Sharrow et al. (2016) convert our probabilistic projections of life expectancy to age-and sex-specific mortality rates using model life tables for countries with an HIV/AIDS epidemic (Sharrow, Clark, and Raftery 2014) . Probabilistic projections of population size are then made using the cohortcomponent method (Raftery, Alkema, and Gerland 2014; Ševčíková and Raftery 2016) .
One limitation of our method is the quality of the ART coverage data and projections. As ART coverage is relatively new and hard to measure, the data we have is noisy. Improvements in ART data quality would likely result in improvements in projections for the generalized HIV epidemic countries. Given high-quality data, our method could also be extended to account for other covariates that explain changes in life expectancy. The data would need to be available for every country used in model fitting back to 1950. Methodology for projecting the covariates would also be required. (1) in blue and equation (2) in red. The solid lines represent medians, and the dashed lines are the 95% intervals. After accounting for HIV prevalence and ART coverage, we see an initial recovery of life expectancy to pre-epidemic levels followed by a steady rise through the end of the century. The right panel shows the single trajectory of past estimates of HIV we use in model fitting in black. In red we have the median, 80% interval, and 90% interval of probabilistic trajectories of HIV prevalence from EPP we use in our projections. 
